AZN.UK

10,508

+1.12%↑

GSK

1,432

+0.99%↑

INDV

841.5

-0.65%↓

AZN.UK

10,508

+1.12%↑

GSK

1,432

+0.99%↑

INDV

841.5

-0.65%↓

AZN.UK

10,508

+1.12%↑

GSK

1,432

+0.99%↑

INDV

841.5

-0.65%↓

AZN.UK

10,508

+1.12%↑

GSK

1,432

+0.99%↑

INDV

841.5

-0.65%↓

AZN.UK

10,508

+1.12%↑

GSK

1,432

+0.99%↑

INDV

841.5

-0.65%↓

Search

Oxford Biomedica PLC

Cerrado

303.5 -0.65

Resumen

Variación precio

24h

Actual

Mínimo

296.5

Máximo

307

Métricas clave

By Trading Economics

Ingresos

22M

-11M

Ventas

27M

78M

Margen de beneficios

-13.726

Empleados

850

EBITDA

25M

5M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+118.04% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

8M

316M

Apertura anterior

304.15

Cierre anterior

303.5

Oxford Biomedica PLC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 may 2025, 23:25 UTC

Acciones populares

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 may 2025, 21:57 UTC

Adquisiciones, fusiones, absorciones

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 may 2025, 21:29 UTC

Adquisiciones, fusiones, absorciones

Millicom to Acquire Telefónica's Operations in Uruguay

21 may 2025, 21:01 UTC

Principales Movimientos del Mercado

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 may 2025, 20:51 UTC

Adquisiciones, fusiones, absorciones

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion

21 may 2025, 23:49 UTC

Charlas de Mercado

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 may 2025, 23:37 UTC

Charlas de Mercado

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 may 2025, 23:33 UTC

Adquisiciones, fusiones, absorciones

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 may 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 may 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 may 2025, 23:32 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 may 2025, 23:31 UTC

Adquisiciones, fusiones, absorciones

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 may 2025, 23:30 UTC

Adquisiciones, fusiones, absorciones

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 may 2025, 23:30 UTC

Adquisiciones, fusiones, absorciones

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 may 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 may 2025, 23:28 UTC

Ganancias

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 may 2025, 23:27 UTC

Ganancias

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 may 2025, 23:26 UTC

Ganancias

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 may 2025, 23:26 UTC

Ganancias

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 may 2025, 23:26 UTC

Ganancias

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 may 2025, 23:23 UTC

Adquisiciones, fusiones, absorciones

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 may 2025, 23:22 UTC

Adquisiciones, fusiones, absorciones

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 may 2025, 23:20 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 may 2025, 23:18 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 may 2025, 21:42 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 may 2025, 21:14 UTC

Adquisiciones, fusiones, absorciones

Millicom to Acquire Telefónica's Ops in Uruguay

21 may 2025, 21:07 UTC

Principales Noticias

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 may 2025, 21:06 UTC

Adquisiciones, fusiones, absorciones

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

21 may 2025, 20:59 UTC

Principales Noticias

Walmart to Cut 1,500 Jobs -- WSJ

21 may 2025, 20:52 UTC

Ganancias

Snowflake Stock Pops After Earnings Beat -- Barrons.com

Comparación entre iguales

Cambio de precio

Oxford Biomedica PLC previsión

Precio Objetivo

By TipRanks

118.04% repunte

Estimación a 12 Meses

Media 649.772 GBX  118.04%

Máximo 800 GBX

Mínimo 500 GBX

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Oxford Biomedica PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

2

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Oxford Biomedica PLC

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.